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C
hemoresistance is the main reason
for treatment failure in metastatic
cancers, including hepatocellular
carcinoma.1,2 Hepatocellular carcinoma is
the seventh most common cancer and the
second leading cause of cancer death
worldwide with limited clinical treatment
options.3,4 Cancer stem cells, which are
identified by enhanced tumor-initiation as
well as the ability to self-renew and differ-
entiate into noncancer stem cells, are often
capable of escaping chemotherapy and
cause recurrence.57 One common me-
chanism of chemoresistance in cancer stem
cells is due to ATP binding cassette (ABC)
transporter proteins that are able to recog-
nize and efflux drug molecules.8 Hoechst
dye 33342, a dye substrate for ABC trans-
porters, exploits this chemoresistance me-
chanism to identify cancer stem cells as
poorly stained side-population cells due
to enhanced Hoechst 33342 dye efflux in
multiple cancers, including hepatic cancers.912
Chromosomal amplification of the MYC
locus has been frequently observed in he-
patocellular carcinoma.13 We have pre-
viously demonstrated that chemoresistant
hepatic tumor cancer stem cells driven by
the oncogene MYC were enriched in the
side population fraction and exhibited en-
hanced tumor initiation capacity.14 Hence,
identifying better methods for overcoming
this mechanism of chemoresistance may be
useful in effectively treating MYC-driven
tumors and other tumor types through en-
hanced killing of cancer stem cells.
ABC transporters are able to efflux multi-
ple classes of cancer drugs, including anthra-
cyclines.15 One such anthracycline, Epirubi-
cin, impairs DNA and RNA synthesis as well
as DNA replication and is currently in clinical
trials for hepatic cancer treatment and fa-
vored over its epimer, Doxorubicin, for its
lower cardiotoxicity.16,17 As an ABC transporter
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ABSTRACT Chemoresistance is a primary cause of treatment
failure in cancer and a common property of tumor-initiating cancer
stem cells. Overcoming mechanisms of chemoresistance, particularly
in cancer stem cells, can markedly enhance cancer therapy and
prevent recurrence and metastasis. This study demonstrates that
the delivery of Epirubicin by nanodiamonds is a highly effective
nanomedicine-based approach to overcoming chemoresistance in
hepatic cancer stem cells. The potent physical adsorption of
Epirubicin to nanodiamonds creates a rapidly synthesized and stable nanodiamonddrug complex that promotes endocytic uptake and enhanced
tumor cell retention. These attributes mediate the effective killing of both cancer stem cells and noncancer stem cells in vitro and in vivo. Enhanced
treatment of both tumor cell populations results in an improved impairment of secondary tumor formation in vivo compared with treatment by unmodified
chemotherapeutics. On the basis of these results, nanodiamond-mediated drug delivery may serve as a powerful method for overcoming chemoresistance
in cancer stem cells and markedly improving overall treatment against hepatic cancers.
KEYWORDS: cancer stem cell . drug delivery . nanomedicine . nanodiamond . biomaterials . chemoresistance
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substrate, Epirubicin can be recognized and effluxed
by multiple ABC transporters. Attempts in using broad
ABC transporter inhibitors to overcome multidrug
resistance have yielded disappointing results in clinical
trials, due to unacceptable toxicity, unpredictable
pharmacokinetic interactions among various transporter
family proteins as well as the suppression of physiologic
roles in normal cells.1820 Specific inhibitors, however,
may lead to ineffectiveness where multiple ABC trans-
porters coexpress andconfer chemoresistance in tumors.21
The difficulty of this approach lies in balancing between
toxicity and ABC transporter inhibition efficacy; hence, a
nontoxic method for overcoming chemoresistance that
is nondistinctive among various ABC transporters would
be more ideal, such as nanotechnology-mediated
drug delivery systems. The use of nanotechnology to
improve therapeutic outcomes has been investigated
in a number of biomedical applications, including can-
cer treatment, with great success.2229 Nanomedical
approaches may overcome this mechanism of
chemoresistance, regardless of ABC transporter in-
volved, while not relying on the use of highly specific
small molecule inhibitors.
Nanodiamonds are truncated semioctahedral car-
bon structures with a diameter of approximately
5 nm.30 Nanodiamonds can be processed and func-
tionalized to express a wide variety of chemical
groups.31 When combined with unique multipolar
facet-dependent variations in surface electrostatic po-
tential, these properties allow nanodiamonds to be
loaded with a wide range of compounds including
small molecules, therapeutic and targeting biologics,
genetic material as well as imaging agents such as
gadolinium.3244 The unique facet-dependent varia-
tions in surface electrostatic potential observed in
nanodiamonds also promotes water molecule interac-
tion with nanodiamond surfaces, a property that
results in nanodiamondgadolinium contrast agents
producing among the highest per-gadolinium
relaxivity increases ever reported.38,45 Compared to
other nanocarbon materials, nanodiamonds also ap-
pear to be more biocompatible and well tolerated in
a number of biological systems.4650 Because of these
properties, nanodiamonds have great potential as an
enhanced drug-delivery platform against tumor cells
and chemoresistant tumor cells alike, as has been
previously demonstratedwith other anthracyclines like
Doxorubicin in liver and breast cancer.5053
In this study, we evaluated the use of a nanodiamond
drug delivery platform to deliver the chemothera-
peutic, Epirubicin, and impair tumor growth that
arises from chemoresistant cancer stem cells. Nano-
diamonds were reversibly bound to Epirubicin by
physical adsorption, and the resulting nanodiamond
Epirubicin drug complex (EPND) was characterized
to confirm successful drug loading and that EPND fit
the size and surface charge requirements needed for
passively targeted enhanced permeation and reten-
tionmediated drug delivery. Additionally, mechanisms
that mediate nanodiamonddrug complex uptake as
well as influence nanodiamond drug release were
further elucidated. Most importantly, EPND exhibited
higher efficacy compared to unmodified standard
chemotherapeutic in killing both normal cancer cells
and cancer stem cells, which resulted in effective
inhibition of secondary tumor formation. This work
suggests that an nanodiamonddrug delivery plat-
form may have clinical potential in treating cancers
driven by chemoresistant cancer stem cells.
RESULTS AND DISCUSSION
NanodiamondDrug Synthesis and Characterization. The
passively targeted delivery of Doxorubicin by nanodia-
monds can effectively enhance therapeutic efficacy
and safety against multiple models of cancer.50 Com-
pared to other nanoparticles, the simple preparation
process is an advantage of nanodiamonds as a drug
delivery platform. As shown in Figure 1a, EPND was
prepared by mixing nanodiamonds and Epirubicin at a
weight ratio of 5:1 (nanodiamond:Epirubicin) under
base conditions and shaking. The nanodiamond sur-
face could be deprotonated by NaOH and promoted
the potent loading of Epirubicin onto nanodiamonds
with an Epirubicin loading efficiency of 19.66 ( 0.2%
(Epirubicin/nanodiamond wt %) (Supporting Informa-
tion Figure S1b), which means that 1 mg of nanodia-
mond can adsorb 0.2 mg of Epirubicin. Further
calculation showed that the number of Epirubicin per
nanodiamond is approximately 15. The stable high
loading efficiency of Epirubicin with minimal fabrica-
tion steps suggest that the optimized reaction condi-
tions were appropriate for EPND synthesis and even
scalable production.54
Prior to functional evaluation of EPND, successful
drug loading onto nanodiamonds was assessed. Four-
ier transform infrared spectroscopy analysis was per-
formed todetermine thevarious surface functional groups
on Epirubicin, nanodiamond and EPND (Figure 1b).
The Epirubicin spectra showed CH stretch signals
around 2900 cm1, CdO stretch signals around
1730 cm1, as well as CdC stretch signals between
1400 and 1600 cm1 that are characteristic of the
aromatic rings of anthracyclines. The nanodiamond spec-
tra showed OH stretch vibrations around 3410 cm1
and OH bend vibrations around 1625 cm1. Func-
tional groups on EPND shared similar peak ranges of
both benzene rings of Epi, as well as hydroxyl groups of
nanodiamond. Thus, Fourier transform infrared spec-
troscopy analysis confirmed the successful loading of
Epirubicin onto nanodiamonds, as the EPND complex
gained the specific surface functional group of both
Epirubicin and nanodiamonds. Nanodiamonds and
EPND were also visualized using transmission electron
microscopy.
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The lattice structure, which was formed by
regular alignment of carbon atomwas clearly observed
on nanodiamond surface but less visible on EPND
after Epirubicin loading (Supporting Information
Figure S2).
Nanoparticledrug complex size and surface
charge can greatly influence blood circulation, tissue
distribution, clearance and passive targeting to tumor
sites, all factors that will ultimately influence the suc-
cess of a nanoparticledrug delivery platform in the
Figure 1. Characterization of nanodiamond, Epirubicin, EPND complex and release profile of Epirubicin. (a) Schematic model
showing surface and chemical structure of nanodiamond (ND) and Epirubicin (Epi), synthesis and aggregation of EPND. ND
represented in truncated octahedron structure with different surface charge denoted with color. ND surface functional group
indicated, including benzene ring, carboxyl group and hydrogen group. Molecular skeleton representing carbon, oxygen and
nitrogen atoms in Epi molecule was shown in red. Synthesis of EPND was performed under basic condition of 2.5 mM NaOH
throughphysical adsorptionbetweenEpi andND. Aggregation around90nmwas formedafter EPNDsynthesis. (b) FTIR spectra of
ND (black line), Epi (red line), and EPND (blue line) indicating surface functional groups. Black arrows indicating surface functional
groups of OH stretch signals between 3300 and 3500 cm1 and CdC stretch signals between 1400 and 1600 cm1 presenting
aromatic rings of anthracyclines. (c) Size distribution of ND (10.9 ( 3.6 nm) and EPND (89.2 ( 3.3 nm) after Epirubicin loading
analyzed via dynamic light scattering (DLS) analysis. Data are represented asmean( SD. (d) Zeta-potential of ND (48.6( 3.3) and
EPND (19.6( 1.1) indicating surface charge. Data are represented asmean( SD; ***, p< 0.001; ****, p< 0.0001. (e) Release profile
of Epi fromEPNDunder variouspHconditions. Epi elutionwasevaluatedover aperiodof7dunderpH2, 4, 7, 10, and12conditions.
Data are representedasmean(SD. (f) Releaseprofile of Epi fromEPNDunderdifferent FBS concentrationsover aperiodof7d. Epi
elution was the most in 10% FBS. Data are represented as mean ( SD; ***, p < 0.001. (g) Free Epi concentration in mice serum
following Epi or EPND injection. Data are represented as mean ( SD; *, p < 0.05.
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clinical setting.5560 Dynamic light scattering analysis
and zeta-potential analysis were applied to nanodia-
mond and EPND complexes to measure particle size
and surface charge (Figure 1c and 1d). When distrib-
uted in water, nanodiamonds interact with water mol-
ecules and other nanodiamond particles through both
negatively and positively charged surfaces and form
aggregates.45,61 The average diameter of nanodiamond
aggregates was 10.9 ( 3.6 nm, while the zeta potential
analysis showed that the surface of nanodiamonds was
positive chargedwith an average particle value of 48.6(
3.3mV. After adsorbing Epirubicin on the nanodiamonds
surface, the zeta potential of the particles decreased to
19.6 ( 1.1 mV, and the diameter increased to 89.2 (
3.3nm. Theadsorptionof Epirubicin leads to thedecrease
of zeta potential of nanopaticle, which further lead to an
increase in complex diameter. A higher level of zeta
potential results in greater electrostatic repulsion forces
between the particles. This repulsion leads to greater
separationdistancesbetweenparticles in the suspension,
reducing aggregation/flocculation caused by van der
Waals interactions. Inversely, the lower zeta potential of
nanoparticles will lead to aggregation and further in-
crease in the size of the complex.
Effect of pH and Protein on NanodiamondDrug Release.
For the successful application of nanodiamonds as a
drug delivery platform, it is important that specific and
sustained drug release occur only upon reaching the
target site. Premature release of Epirubicin will induce
toxicity in the blood circulatory system, cause damage
to normal cells and tissues or result in metabolic
breakdown.62 The nanoparticlesmay interact with cells
in the body, where the pH ranges from 7.4 to 4.5.63,64
Thus, understanding the effect of environmental
pH stimuli on nanodiamond-mediated drug release
is important when minimizing toxicity toward
normal tissue and cells. Epirubicin release from EPND
was analyzed in a series of pH conditions (Figure 1e).
Epirubicin was released rapidly and abundantly (>80%
within first 9 h) in extremely acidic conditions (pH = 2)
while maintaining a sustained release in pH 4. In
neutral pH conditions (pH= 7), releasewas significantly
lower than that in pH 4 (p-value < 0.001) and pH 2
(p-value < 0.0001) and was strongly inhibited in pH 10
and 12 conditions. This data suggests that the release
of Epirubicin is accelerated by acidic conditions and
attenuated under neutral or basic conditions.
Besides pH, intracellular nanodiamondprotein in-
teractions may also play an important role in the
release of Epirubicin from nanodiamond surface as
charged proteins have been demonstrated to compe-
titively bind to nanodiamonds and affect surface
charge as well as nanodiamond particle aggregation.65
In order to better understand the effect of proteins
on drug release, Epirubicin release from EPND was
measured following incubation in a series of fetal
bovine serum (FBS) concentrations from 0.1 to 10%.
Drug release was proportionally related to FBS con-
centration with higher concentration of FBS (10 and
5%) facilitating the release of Epirubicin compared to
that of 0% FBS (Figure 1f, Supporting Information
Figure S3) (p-value < 0.001). This data demonstrates
that proteins can competitively bind to nanodiamonds
and further enhance Epirubicin release.
While proteins may influence nanodiamond drug
release, we investigated if this could affect premature
nanodiamond drug release in serum in vivo. While
Epirubicin drug was significantly detectable in serum
at 1 and 6 h post-treatment (p-value < 0.05), free
Epirubicin drug was not detectable in EPND-treated
mice (Figure 1g). Under physiological conditions, the
pH levels are strictly ordered and different among
various organs, tissues, and even organelles. It is prac-
tical to apply the release profile of EPND onto various
physiological conditions, such as in the blood circula-
tion system where pH is among 7.357.45. Premature
drug release in blood could contribute to toxic side-
effects such as hematic disorder, cardiac failure or other
damages to normal cells and tissues.66 Because of the pH-
dependent nature of EPND drug release, the release of
Epirubicin is likely inhibited in biological systems under
neutral to basic pH, such as the blood circulatory system.
The lack of active drug-release in the bloodmay serve as a
contributing mechanism of the enhanced safety and lack
of myelosuppression previously observed following pre-
clinical nanodiamondanthracycline treatment.29 Follow-
ing uptake of EPND by tumor cells, intracellular proteins
can facilitate the release of drug from nanodiamond plat-
form, particularly in acidic conditions. Taken together, the
acid/protein-promoted release profile of nanodiamond
drug should contribute to limiting systemic toxicity while
mediating more tumor-specific intracellular drug release.
Mechanism of NanodiamondDrug Cellular Uptake. Fol-
lowing physical characterization of EPND, we investi-
gated the mechanism by which EPND is taken up by
tumor cells. Previous studies have found that endocy-
tosis plays a key role in lipid nanoparticle uptake,
particularly clathrin-mediated-endocytosis andmacro-
pinocytosis.67,68 The clathrin-mediated-endocytosis
pathway involves the binding of cell-surface receptors
with extracellular cargos, followed by sequestration
through intracellular adaptors that help form endosomes
that mature into lysosomal organelles after fusion with
primary lysosomes.69 Macropinocytosis, another form of
endocytosis, is processed through forming intracellular
vesicles by closing the waving cell surface ruffles back to
plasma membrane, which provides sufficient transporta-
tion for extracellular fluid bulks and macromolecules.70
Another clathrin-independent form of endocytosis is
caveolae-mediated endocytosis, which is characterized
as a caveolin-containing, clathrin-independent endocyto-
sis pathway that is essential for transportation of certain
molecules such as cholera and albumin.71 In order to
investigate whether EPND complexes enter cells by one
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or more endocytic mechanisms, inhibitors of these path-
wayswere used to test their effect on cellular EPNDuptake
in LT2-MYC, a cell line derived from liver tumors of Tet-
o-MYC/LAP-tTA (LT2-MYC) mice.72,73
Contribution of clathrin-mediated-endocytosis in
EPND uptake was evaluated by pretreating LT2-MYC
cells with dynasore (100 nM), which is an inhibitor of
GTPase required for clathrin-mediated-endocytosis,
followed by 30 min treatment with 35 μM EPND.74
Normally, EPND is readily taken up by tumor cells,
however, inhibition of clathrin-mediated-endocytosis
impaired this uptake by 46.8% (p-value < 0.05) (Figure 2a
and 2b). Similar steps were taken to evaluate the
contribution of macropinocytosis in EPND uptake by
treating cells with 5-(N-ethyl-N-isopropyl) amiloride,
the inhibitor of macropinocytosis, and Filipin, the
inhibitor of caveolae-mediated endocytosis.68,75 Fol-
lowing inhibition of macropinocytosis, no detectable
Figure 2. EPND uptake is mediated by multiple endocytic pathways. (a) Representative images of cellular EPND uptake after
dynasore treatment by fluorescentmicroscopy. LT2-MYC cells treatedwith or without dynasore (100 μM) for 30min followed
by 30 min treatment with 35 μM EPND (upper panels) or PBS control (bottom panels). Blue and red fluorescent signals
represent diamidino-2-phenylindole (DAPI) staining and Epirubicin (Epi) respectively. Scale bar (white), 50 μm. (b)
Quantification of percent cellular EPND uptake normalized to DAPI signal (n = 3 per treatment condition). Data are
represented as mean ( SD; *, p < 0.05. N.D. denotes nondetectable signal. (c) Representative images of cellular EPND
uptake after 5-(N-ethyl-N-isopropyl) amiloride (EIPA) treatment by fluorescent microscopy. LT2-MYC cells treated with or
without EIPA (50 μM) for 30min following by 30min treatmentwith 35 μMEPND (upper panels) or PBS control (bottompanels).
Blue and red fluorescent signals represent DAPI staining and Epi, respectively. Scale bar (white), 50 μm. (d) Quantification of
percent cellular EPNDuptake normalized toDAPI signal (n = 3 per treatment condition). Data are represented asmean( SD; **,
p < 0.01. N.D. denotes nondetectable signal. (e) Representative images of cellular EPND uptake after Filipin treatment by
fluorescent microscopy. LT2-MYC cells treated with or without Filipin (50 μg/mL) for 30min followed by 30min treatment with
35 μM EPND (upper panels) or PBS control (bottom panel). Blue and red fluorescent signals represent DAPI staining and Epi,
respectively. Scale bar (white), 50 μm. (f) Quantification of percent cellular EPND uptake normalized to DAPI signal (n = 3 per
treatment condition). Data are represented as mean ( SD. N.D. denotes nondetectable signal.
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levels of EPND were found in tumor cells (p-value <
0.01) suggesting that macropinocytosis is required for
EPND uptake (Figure 2c and 2d). However, no signifi-
cant change in Epirubicin signal was detected following
Filipin inhibition, indicating that caveolae-mediated en-
docytosis likely does not play a role in EPND uptake
(Figure 2e and 2f).
These results suggest that while clathrin-mediated-
endocytosis inhibitors can impair EPND uptake, macro-
pinocytosis is critical to EPND uptake. Inhibition of
clathrin-mediated-endocytosis has previously been
shown to affect macropinocytosis.76 This could explain
the partial inhibitionof EPNDuptake followingdynasore
treatment. During the process of macropinocytosis, the
maturation of macropinosomes is accompanied by
fusion with tubular lysosomes, and the internal pH
decreases to 45.77Upon entering cells throughmacro-
pinocytosis, EPND particles are encapsulated by macro-
pinosomes that fuse with lysosomes, resulting in an
acidification of the nanodiamonddrug environment,
which could stimulate a sustained release of drug
according to nanodiamondEpirubicin release pro-
files at pH 4 with the help of intracellular proteins.64
Although further studies are needed, the EPND release
profile suggests that a low concentration of free drug
molecule in serum can be expected, since Epirubicin
would not be efficiently released fromnanodiamond in a
pH of 7.4.63 The ladder of pH from blood to lysosome
should facilitate intracellular specific delivery of Epirubi-
cin by nanodiamonds. Thus, the mechanisms of nano-
diamond drug release and cellular uptake contribute to
an improved drug delivery of Epirubicin by nanodia-
monds by reducing extracellular drug concentration
and stimulating a sustained and continuous drug release
following nanodiamonddrug tumor cell uptake.
Enhanced NanodiamondDrug Cellular Retention. ABC
transporters mediate chemoresistance by recognizing
specific structure and charge properties on molecules
such as Epirubicin and effluxing them out of tumor
Figure 3. Cellular drug retention in hepatic tumor cell line
of EPND and Epirubicin. (a) Representative images of cel-
lular drug retention in LT2-MYC cells by fluorescent micro-
scopy. LT2-MYC cells treated with Epirubicin (Epi) (35 μM),
EPND (35 μM) or LiposomalEpirubicin (Lipo-Epi) (35 μM)
for 1 h before 12 h efflux. Blue and red fluorescent signals
represent diamidino-2-phenylindole (DAPI) staining and
Epirubicin, respectively. Scale bar (white), 50μm. (b) Cellular
retention is quantified by percent of drug retention normal-
ized to DAPI signal (n = 3). Data are represented as mean(
SD; *, p < 0.05; **, p < 0.01; ***, p < 0.001. N.D. denotes
nondetectable signal.
Figure 4. Evaluation of EPND efficacy in vitro. (a) Dose
response curves of LT2-MYC cells after exposure to PBS,
nanodiamond (ND) and a range of Epirubicin (Epi) and EPND
concentrations. IC50 of Epi =16nM, IC50 of EPND=450nM.Data
are represented as mean ( SD. (b) Live cell number counting
during 5 days of PBS, ND, Epi (100 nM) and EPND (100 nM)
treatment. Data are represented as mean( SD, *, p < 0.05. (c)
TUNEL analysis of LT2-MYC cells after Epi and EPND treatment
at IC25, IC50, and IC90 concentrations respectively with ND and
PBS as control. Green andblue fluorescent signals representing
apoptosis by fluorescein isothiocyanate (FITC)/TUNEL staining
and diamidino-2-phenylindole (DAPI) staining, respectively.
Scale bar (white), 50 μm.
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cells, thus impairing drug efficacy. When drug is bound
to the nanodiamond surface, however, the nanodia-
monddrug complex differs greatly from unmodified
drugmolecules in terms of both size and structure. The
effect of nanodiamonddrug loading on cellular re-
tention of Epirubicin was evaluated. LT2-MYC cells
were treated with equal amounts of Epirubicin and
EPND (35 μM) for 1 h, washed and subsequently
allowed to efflux drugs for 12 h and Epirubicin signal
was analyzed. While there was significant uptake of
both Epirubicin and EPND within 1 h, there was
significantly less intracellular Epirubicin in tumor cells
and significantly more extracellular Epirubicin when
treated with unmodified Epirubicin compared to
EPND-treated cells when allowed to efflux for 12 h
(Figure 3a and 3b, Supporting Information Figure S4).
Additionally, the amount of intracellular Epirubicin in
EPND-treated tumor cells was not significantly affected
by the efflux period and no detectable Epirubicin was
measured in the supernatant further demonstrating
Figure 5. Enhanced efficacy of EPND against side population cells in vitro. (a) Representative images of flow cytometry
analysis of side-population (SP) in LT2-MYC cell line after 48 h of Epirubicin (Epi) (100 nM and 200 nM) or EPND (100 nM and
200 nM) treatment using Hoechst dye 33342 staining, PBS and nanodiamond (ND) as control. SP gate was determined by
absence of cell population after addition of 500 μMverapamil in PBS control. The percentages of SP cells in the total live cells
gated are shown. (b) Quantitative analysis of SP cells in LT2-MYC cell line after 48 h of Epi, EPND, PBS andND treatment (n= 3).
Data are represented as mean ( SD, *, p < 0.05; **, p < 0.01. (c) Colony-forming units (CFU) spheroid assay of sorted SP cell,
non-SP cells and total cells performed in serum free DMEM7days after PBS, ND, Epi (50 nMand 100 nM) and EPND (50 nMand
100 nM) treatment (n = 5). Data are represented asmean( SD, **, p < 0.01; ***, p < 0.001. (d) Representative images of colony
spheroids formed by SP cells treated with PBS, ND, Epi and EPND. Scale bar, 50 μM.
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the potent enhanced drug retention mediated by
nanodiamond drug-delivery (Figure 3a and 3b, Sup-
porting Information Figure S4). Drug retention analysis
demonstrates that Epirubicin loading onto nanodia-
monds enhances retention in tumor cells. One possible
explanation is that due to the structural constraints of
EPND, the nanodiamonddrug complexes no longer
meet the requirement for ABC transporter substrates;
hence, the drug efflux by ABC transporter protein is
restrained and the drug is able to remain within
cells for longer period when bound to nanodiamond
and released in a slow and sustained manner. Further-
more, this is a function that is specific to nanodiamond-
mediated drug delivery as Epirubicin delivery by the
Figure 6. Nanodiamond delivery of Epirubicin can effectively target side population cells in murine liver tumor models. (a)
Schematic diagram showing themurinemodel for MYC-driven tumor induction, long-term drug treatment and experimental
workflow. MYC-driven tumor was induced in 6-week old female FVB/N mice by hydrodynamic transfection. Six weeks after
transfection, mice were treated with PBS (n = 4), nanodiamond (ND) (1mg/kg, n = 5), Epirubicin (Epi) (5 mg/kg, n = 5) or EPND
(5 mg/kg, n = 5) via tail vein (i.v.) injection every 3 d. Tumors were isolated for further analysis 3 d after the final drug
treatment. (b) Representative images of flow cytometry analysis of side population (SP) cells inMYC-driven tumor tissue after
Epi, EPND63 and ND treatment using Hoechst dye 33342 staining, PBS as control. SP gate was determined by absence of cell
population after addition of 100 μM verapamil in PBS control. The percentages of SP cells in the total live cells gated are
shown. (c) Quantitative analysis of SP cells in MYC-driven tumor tissue after Epi, EPND, ND and PBS treatment (n = 3). Data are
represented as mean ( SD; *, p < 0.05. (d) Representative microscopic images showing histological morphology and
apoptotic response in normal liver tissue andMYC-driven tumor tissue after drug treatment: hematoxylin and eosin staining
(H&E) (top row), bright-field (BF) image (second from the top row), fluorescein isothiocyanate (FITC) signal indicating
apoptosis by TUNEL staining (third from the top row), and diamidino-2-phenylindole (DAPI) staining (bottom row). White
dotted line denotes boundaries between tumor and adjacent normal liver tissue. Scale bar, 100 μm. (e) Quantification of
percent apoptosis signal over DAPI staining (n = 3). Data are represented as mean ( SD; *, p < 0.05; **, p < 0.01.
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broadly usednanomaterial liposomal vesicles (Liposomal
Epirubicin) failed to enhance drug retention when
compared to unmodified Epirubicin or EPND (p-value
< 0.01) (Figure 3a and 3b).
In Vitro Evaluation of NanodiamondDrug Efficacy Against
Cancer Stem Cells. Apoptosis induced by Epirubicin and
other anthracycline drugs is achieved through inter-
calating of anthracyclines between DNA and RNA base
pairs resulting in interference of transcription and
translation as well as the generation of reactive oxygen
species.78 In order to validate the biological function of
drug released from nanodiamond platform, cellular
proliferation and apoptosis analysis of EPND was per-
formed. Following treatment of LT2-MYC cells with a
range of Epirubicin and EPND concentrations, we
determined the half maximal inhibitory concentration
(IC50) values of Epirubicin and EPND to be 16 nM and
450 nM respectively (Figure 4a). The 30-fold increase in
IC50 for EPND as compared to Epirubicin in a closed
in vitro system is a result of slow and sustained release
of Epirubicin from EPND, which may contribute to
enhanced Epirubicin retention in tumor cells. Longer-
term treatment of LT2-MYC cells confirmed this
delayed apoptotic effect. While there is significant
difference in cell viability between Epirubicin and
EPND treated cells at day 2 and day 3 (p-value <0.05),
Epirubicin and EPND both caused more than 90% cell
death byday 5 suggesting that although thedrug release
from nanodiamonds was sustained and slow, it even-
tually caused equivalent cell death in a closed system
(Figure 4b). Induction of apoptosis by Epirubicin and
EPNDwas confirmed by terminal deoxynucleotidyl trans-
ferasemediated deoxyuridine triphosphate nick end
labeling (TUNEL) staining (Figure 4c). Apoptosis and
growth inhibition detected following nanodiamond
drug treatment demonstrated that drug had been re-
leased from the nanodiamond vehicle and the biological
function of Epirubicin was not impaired or altered by its
adsorption onto the nanodiamond platform.
Following confirmation that EPND can enhance
retention of Epirubicin in tumor cells and induce
apoptosis, the effect of EPND on chemoresistant can-
cer stem cells was evaluated. Previously, we demon-
strated that MYC-driven hepatic tumors have a strong
side population cell population that is enriched for
cancer stem cells with tumor-initiation ability.14 The
effect of Epirubicin and EPND treatment on side po-
pulation cells in these MYC-driven hepatic tumors was
analyzed. LT2-MYC cells were treated with Epirubicin
and EPND for 48 h prior side population analysis.
Epirubicin treatment of LT2-MYC cells resulted in a
significant increase in side population cells compared
to control treated cells (p-value <0.01), while EPND
treatment resulted in a significant decrease in side
population percentage (p-value < 0.05) (Figure 5a and
5b). In order to confirm that the side population and
nonside population were cells and not cellular debris
following drug treatment, LT2-MYC cells were sorted
and analyzed with live cell-specific Calcein AM dye to
confirm that viable surviving cells were gated and
analyzed (Supporting Information Figure S5). The in-
crease in side population cell percentage following
Epirubicin treatment suggests that Epirubicin treat-
ment preferentially kills nonside population cells while
sparing chemoresistant side population cells. In
contrast, the lack of increase in side population cell
percentage following EPND treatment suggests that
the enhanced retention of EPND in tumor cells allows
for equal, if not greater, killing of chemoresistant side
population cells. Because tumor-initiation is a hallmark
of cancer stem cells, the ability of Epirubicin and EPND
Figure 7. EPND is less toxic than Epirubicin. (a) Bodyweight
analysis of MYC-tumor bearing mice injected with PBS,
nanodiamond (ND), Epirubicin (Epi) (5 mg/kg) and EPND
(5 mg/kg) (n = 5) every 3 days. Black arrow denotes injec-
tion day. Data are presented as mean( SD. (b) Bodyweight
analysis of healthy FVB/N mice injected with PBS, ND, Epi
(20 mg/kg) and EPND (20 mg/kg) (n = 5) every 3 days. Black
arrow denotes injection day. Data are presented as mean(
SD; **,p<0.01; ***.p<0.001. (c) KaplanMeier survival plot of
healthy FVB/N mice injected with PBS, ND, Epi 20 (20 mg/kg)
and EPND 20 (20 mg/kg) (n = 5) every 3 days. Mice were
sacrificed once bodyweight loss exceeded 20%. **, p < 0.01.
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to impair colony formation in vitro was evaluated.
While sorted side population cells could form more
colony forming units compared to nonside population
and unsorted LT2-MYC cells, EPND treatment at both
50 and 100 nM resulted in a significant reduction in
both size and total of number of colony forming
units by side population cells compared to phosphate
buffered saline (PBS) (p-value < 0.01, p-value < 0.001)
(Figure 5c and 5d). Meanwhile, the number and size of
colony forming units of Epirubicin-treated side popula-
tion cells were not significantly affected compared to
PBS and were significantly more than EPND-treated
side population cells (p-value < 0.001), suggesting that
side population-enriched cancer stem cells could es-
cape and survive in Epirubicin 50 nM treatment and
continue to proliferate (Figure 5c and 5d). This data
provides evidence that nanodiamonddrug delivery
may be an effective method for overcoming chemore-
sistance in cancer stem cells and target both bulk
tumor cells aswell as tumor-initiating cancer stem cells.
In Vivo Evaluation of NanodiamondDrug Efficacy Against
Cancer Stem Cells. After confirming that EPND can en-
hance cellular drug retention and effectively target
chemoresistant cancer stem cells in MYC-driven tumor
cells in vitro, the effect of EPND compared to unmodi-
fied Epirubicin was evaluated in vivo in amurinemodel
of MYC-induced hepatic cancer that we previously
demonstrated enriched for tumor-initiating chemore-
sistant cancer stem cells in the side population
population.14 Following induction of MYC-driven tu-
mors, tumor-bearing mice were treated with either
Epirubicin (5 mg/kg) or EPND (5 mg/kg Epirubicin
equivalent) or controls over a 12 d period and tumors
were subsequently isolated for side population analysis
(Figure 6a). Consistent with in vitro experiments, Epirubi-
cin treatment resulted in an increase in the percentage of
side population cells while EPND treatment resulted in a
decrease in the side population percentage (Figure 6b
and 6c). Thus, EPND can effectively target and kill both
nonside population and side population cells in primary
hepatic tumors, while unmodified Epirubicin preferen-
tially kills nonside population cells.
Apoptosis analysis was performed to determine if
the alterations in side population percentages in vivo
were due to effective killing of primary hepatic tumor
cells. A strong apoptotic responsewas detected in both
Epirubicin and EPND treated tumors while nanodia-
mond and PBS treated tumors showed minimal apop-
tosis (Figure 6d and 6e). Additionally, apoptosis
following EPND treatment was limited to tumor tissue
and not adjacent normal hepatic tissue, suggesting
that nanodiamonds can serve as an effective and safe
drug-delivery platform to target and eliminate non-
cancer stem cells as well as chemoresistant cancer
Figure 8. EPND can inhibit tumor-initiation in murine hepatic tumor allografts. (a) Representative image of FVB/N mouse
seeded in hindquarters with cells from PBS, nanodiamond (ND), Epirubicin (Epi) or EPND treated MYC-driven tumors 58 days
after allograft transplantation. Two mice in each panel were under same treatment conditions. Black arrows indicate
treatment condition and number. (b) Quantitative analysis of percentage allograft tumor formation in FVB/N mice injected
with cells fromdrug treatedMYC-driven tumors (n = 10 per treatment condition). Data are represented asmean. N.D. denotes
nondetectable tumor. (c) Quantitative analysis of allograft tumor volumes in FVB/Nmice injectedwith cells fromdrug treated
MYC-driven tumor (n = 10 per treatment condition). Data are represented as mean( SD. N.D. denotes nondetectable tumor.
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stem cells (Figure 6d). Furthermore, bodyweight anal-
ysis in tumor-bearing mice during the treatment de-
monstrated that while systemic toxic effects of
Epirubicin result in notable weight-loss and PBS and
nanodiamond treatment resulted in ineffective ther-
apy and continuous tumor growth seen in notable
weight-gain, EPND treatment resulted in no weight
loss due to both a lack of systemic toxicity as well as
effective tumor treatment (Figure 7a). The effect of
Epirubicin loading onto nanodiamonds on overall
toxicity was also evaluated by analyzing bodyweight
and survival of FVB/N mice following high dosage
treatment of Epirubicin or EPND (20 mg/kg). High
Epirubicin dosages caused significant decrease in
bodyweight and acute chemotherapy-related death
where equivalent concentration of EPND resulted in no
difference compared to PBS control (Figure 7b and 7c)
(p < 0.001). Moreover, administration of the nanodia-
mond vehicle alone showed no effect in side popula-
tion proportion (Figure 5a, 5b, 6b and 6c), cell viability
(Figure 4a and 4b), bodyweight and survival (Figure 7b
and 7c) as well as in apoptotic response (Figure 4c, 6d
and 6e) in vitro and in vivo suggesting that this carbon
nanoparticle can serve as a safe drug delivery platform.
We have previously demonstrated that treatment
with unmodified drugs that are ABC transporter sub-
strates results in the preferential elimination of nonside
population cells and an increased selection for tumor-
initiating side population cells among the surviving
tumor cells.14 Tumor-initiation of surviving tumor cells
following Epirubicin and EPND treatmentwas analyzed
to determine if EPND treatment can more effectively
overcome this selection for chemoresistant cancer
stem cells that are required for secondary tumor for-
mation and recurrence. While Epirubicin treatment
resulted in enhanced tumor-initiation in allografts
when seeded at 300 cells per injection, EPND treat-
ment successfully prevented secondary allograft tu-
mor formation (Figure 8a, 8b and 8c). These results
demonstrate that EPND can serve as an effective
method for overcoming chemoresistance in cancer
stem cells and prevent the characteristic tumor-
initiation of surviving cancer stem cells that contribute
to recurrence and metastasis.
CONCLUSION
Our study provides strong evidence that nanodia-
monds can serve as an excellent platform for enhanced
chemotherapeutic delivery, particularly in the treat-
ment of chemoresistant cancer stem cells. Under opti-
mized synthesis conditions, nanodiamonds are able to
load anthracycline drugs such as Epirubicin with high
affinity and efficiency. The resulting nanodiamond-
drug complex, EPND, possesses the necessary proper-
ties in size and surface charge to facilitate passively
targeted delivery into tumor tissues as well as avoid
clearance by phagocytic cells. Moreover, the mechan-
isms of EPND drug release and uptake likely play an
important role in enhancing intratumoral drug release.
When the nanodiamonddrug complex encounters an
acidic environment, the affinity between Epirubicin and
nanodiamond decreases so that Epirubicin disassociates
fromnanodiamond surface. Intracellular chargedproteins
can also stimulate the detachment of Epirubicin from
nanodiamond. These drug release mechanisms coordi-
nates with macropinocytosis-mediated cellular uptake to
ensure intracellular-specific drug release,minimizing toxic
side-effects associated with high levels of free anthracy-
cine in the blood circulatory system.
The association of Epirubicin to nanodiamonds pre-
vents efflux of Epirubicin by ABC transporters, allowing
for enhanced cellular retention that leads to cell death
in both chemoresistant cancer stem cells and noncan-
cer stem cells and effective impairment of cancer stem
cell-mediated tumor-initiation. While more preclinical
work in murine and large animal models are needed
before nanodiamondanthracycline drug delivery can
be translated into the clinic, the work presented here
demonstrates the benefits of an nanodiamond-based
drug delivery platform in biomedical applications,
particularly against chemoresistant cancer stem cells.
Because of the versatility of an nanodiamond-based drug
delivery platform, future application of nanodiamonds
could expand its conjugations and functional modifica-
tions including the addition of other ABC transporter
effluxed drugs as well as active targeting components
such as antibodies or peptides against tumor cell surface
proteins for targeted drug release.43,7981 Additionally, the
application of a nanodiamonddrug delivery system is
not limited tohepatocellular carcinomaand likelywill beof
benefit to variousmalignant cancer typeswhere chemore-
sistance is commonly associated with ABC transporter
overexpression.82,83 Compared to small molecule ABC
transporter inhibitors, this nanodiamond drug-delivery
platform can reduce toxicity primarily through passive
targeting to increase tumor-specific drug concentra-
tion and improve efficacy by enhancing retention of
the drugs within the correct cell compartments. As
such, a nanodiamond drug-delivery platform is a pro-
mising nanomedical approach to treating a broad
range of difficult cancers, particularly those driven by
chemoresistant cancer stem cells.
MATERIALS AND METHODS
Materials. NanoAmando Soft Hydrogel containing nanodia-
monds was purchased from NanoCarbon Research Institute
(Nagano, Japan). Epirubicin, Verapamil, 5-(N-ethyl-N-isopropyl)
amiloride, Propidium Iodide, Hoechst Dye 33342, Filipin and
Dynasorewas purchased from Sigma-Aldrich (MO, USA). Roswell
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ParkMemorial Institute 1640 (RPMI-1640) and Calcein AMdyewere
purchased from Thermo Scientific (MA, USA). Fetal Bovine Serum
(FBS) was purchased from Biowest (Nuaillé, France). Penicillin/
Streptomycin was purchased from Life Technologies (CA, USA).
(3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) MTS assay was purchased
from Promega (WI, USA). Red Blood Cell lysis buffer was
purchased from eBioscience (CA, USA). Spectra/Por Dialysis
membrane tubing (MWCO 68000 kDa) was purchased from
Spectrum Laboratories (Shanghai, China).
Preparation of NanodiamondDrug Complex. NanoAmando Soft
Hydrogel was freeze-dried to obtain nanodiamond powder.
nanodiamond powder was resuspended in deionized water
to form nanodiamond solution (5 mg/mL) and autoclaved. To
form nanodiamonddrug complex, nanodiamond solution
(5 mg/mL) and Epirubicin (1 mg/mL) were mixed at a weight
ratio of 5:1 (nanodiamond:Epirubicin), and NaOH solution was
added to until the final concentration of NaOH is 2.5 mM.
Following reaction at room temperature, the mixture was
centrifuged for 15 min at 15,000 rpm, room temperature.
Subsequently, the pelleted EPNDwas resuspended in deionized
water. Unbound Epirubicin remaining in the supernatant was
quantified by measuring absorbance at 485 nm using the
Infinite 200 PRO (Tecan, Zurich, Switzerland). Loading efficiency
of Epirubicin was then calculated from the absorbance of
Epirubicin at 485 nmwavelength which linearly correlated with
Epirubicin concentration. A standard curve was established by
serial dilution of Epirubicin ranging from 0 to 1 mM to attribute
absorbance measurements to Epirubicin concentration. The
calculation of the number of Epirubicin per nanodiamond is
based on themolecular weight of eprrubicin (MW= 579.98) and
nanodiamonds (MW = 46,583).84
NanodiamondDrug Characterization. Nanodiamonds and EPND
(0.10.2 mg/mL, nanodiamond concentration) were sus-
pended in deionized water within disposable micro cuvettes.
Hydrodynamic size and ζ-potential measurements were per-
formed on a Zetasizer Nano (Malvern, UK). Final values were
averages of three or more separate measurements of each
sample. Fourier transform infrared spectroscopywas performed
using a PerkinElmer FTIR spectrum 2000 over a range of
4004000 cm1. Samples were dried using a rotary evaporator.
Five mg of sample was mixed with 0.1 g of KBr powder using
mortar and pestle before pressing the sample to a thin film of
which the spectra were taken. Transmission electronic micro-
scopy was performed using a JEOL JEM-2010 transmission
electron microscope. The nanodiamond and EPND were soni-
cated in water at a concentration of 0.5 mg/mL, and the
suspension was dropped on the copper grid (coated with
carbon film), then dried overnight at room temperature prior
to imaging.
Preparation and Characterization of LiposomalDrug Complex.
LiposomalEpirubicin synthesis was performed as previously
described using ammonium sulfate gradients and dialysis tub-
ing (MWCO 60008000 kDa).85,86 Lipid (Egg Phosphatidylcho-
line/Cholesterol molar ratio 2:1) was dissolved in chloroform
and dried overnight using a rotary evaporator. Dried lipid was
rehydrated with ammonium sulfate solution and dialyzed over-
night. Epirubicin solution was then added to lipid solution
followed by 3 h of further dialysis. LiposomalEpirubicin was
then filtrated through a 400 μM filter. Loading efficiency
of Epirubicin was Epirubicin concentration was quantified
according to an Epirubicin standard curve in lipid solution.
LiposomalEpirubicin hydrodynamic size and ζ-potential mea-
surements were performed on Zetasizer Nano (Malvern, UK)
with a diameter of 162.8( 3.1 nm and a negative zeta-potential
of4.4( 1.2mV (Supporting Information Table S1). Final values
were averages of three ormore separatemeasurements of each
sample.
NanodiamondDrug Release. Epirubicin release was investi-
gated under a range of pH and protein concentrations in
physiological condition of 37 C. For different pH conditions
of pH 2, 4, 7, 10 and 12, pH of deionized water solutions was
adjusted using HCl and NaOH and tested by pH meter. For
different protein concentrations, 10, 5, 2.5, 1.25, 0.63, 0.3, 0.1 and
0% FBS was added to RPMI as stock solutions. For both pH and
protein concentrations, EPNDwas resuspended in the solutions
and incubated at 37 C until indicated time points. At each
time point, EPND was centrifuged for 15 min at 15 000 rpm and
the supernatant containing unbound epirubicin was collected
for quantification. Quantification was done by measuring the
absorbance wavelength of Epirubicin at 485 nm using the
Infinite 200 PRO (Tecan, Zurich, Switzerland). Two standard
curves were established by serial dilution of Epirubicin in water
or RPMI, ranging from 0 to 1 mM to attribute absorbance
measurements due to Epirubicin concentration (Figure S2a).
After collection of supernatant at indicated time points, EPND
was resuspended in 1 mL of the previously made stock solution
and sonicated for twice at 20 s each before incubation at 37 C
until the next time point. Nanodiamonddrug release was also
measured in vivo. FVB/N mice were injected with 5 mg/kg
Epirubicin or EPND. At different time points (1, 6, 12, 24 and
48 h), whole blood was collected by cardiac puncture. Serum
was collected from supernatant following incubation of blood
on ice for 30 min followed by 30 min of centrifugation at
6000 rpm. Serum Epirubicin concentration was quantified
according to an Epirubicin standard curve in PBS-treated mice
serum (Figure S1a).
Cell Line and Murine Tumor Model. LT2-MYC cell line was derived
from Tet-O-MYC/LAP-tTA (LT2-MYC) murine hepatoblastoma
tumor model from Professor J. Michael Bishop's lab
(University of California, San Francisco), which has been pre-
viously described.72,73 LT2-MYC cell line was cultured in RPMI-
1640 supplemented with 10% FBS and 1% Penicillin/Strepto-
mycin in 37 C with 5% CO2. MYC-induced tumor model was
induced through hydrodynamic transfection as previously
described.14,87 Briefly, 6-week-old female FVB/N mice (InVivos,
Singapore) were injected with 20 μg of pT3-EF1a-flox-MYC
plasmids which encodes MYC, together with 2 μg of pCMV-
HSB2 plasmids which encodes Sleeping Beauty transposase
mixing in 2 mL of 0.9% NaCl. All animal studies were done
according to approved protocols by the NUS Institutional
Animal Care and Use Committee, Singapore.
Evaluation of NanodiamondDrug Uptake and Efflux. For EPND
uptake assay, 1  104 LT2-MYC cells per well were seeded on a
Nunc Lab-Tek 2-well chamber slide and cultured for 24 h at
37 C with 5% CO2 and then pretreated with 100 μM dynasore,
50 μM 5-(N-ethyl-N-isopropyl) amiloride or 5 μg/mL Filipin for
30 min. 20 μM of EPND was then added and treated for 30 min
with culture media as negative control. Cells were then gently
washed with 1  PBS thrice and fixed with 4% paraformalde-
hyde for 10 min at 37 C. Subsequently, fixed cells were stained
with DAPI for 5 min and visualized using an Olympus BX60
fluorescence microscope (Tokyo, Japan). Epirubicin was visua-
lized with the Rhodamine channel at an excitation/emission
wavelength of 482/570 nm. Quantification of fluorescent signal
was performed through ImageJ. Images are converted to binary
color, a threshold for particle counting was set and then the
particle number was counted by ImageJ Analyze particles
function. Triplicate images are analyzed to obtain mean value
and SD.
For EPND cellular retention assay, 1 104 LT2-MYC cells per
well were seeded on a Nunc Lab-Tek 2-well chamber slide and
cultured for 24 h at 37 C with 5% CO2 and then pretreated with
35 μMof Epirubicin, EPND and Liposomal-Epi. PBSwas added as
negative control. For pre-efflux, cells were gently washed with
1  PBS thrice and fixed with 4% paraformaldehyde (PFA) for
10min at 37 C. Subsequently, fixed cells were stainedwithDAPI
for 5 min and visualized using an Olympus BX60 fluorescence
microscope (Tokyo, Japan). Epirubicin was visualized with the
Rhodamine channel at an excitation/emission wavelength of
482/570 nm. For 12 h postefflux, cells were incubated for
another 12 h after 1 h treatment, with 2 to 3 times of PBS
washing. Cells were then fixed and visualized as described in
pre-efflux step.
Evaluating Cell Viability. For cell viability assays, 1.5 103 LT2-
MYC cells were seeded per well in Nunc 96-well plates and
cultured for 24 h at 37 C with 5% CO2. Cells were treated with a
range of Epirubicin or EPND concentrations (0.00005 to 100 μM)
for 72 h where PBS and equivalent nanodiamond were used as
control. Cells were washed once with 1 PBS. Cell viability was
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quantified using 20%MTS solution in clear RPMImedia after 1 h,
at absorbance wavelength of 490 nm in accordance to manu-
facturer's protocol. Background absorbance (wells without any
cells) was subtracted from each sample before calculating the
final absorbance value. Doseresponse curves were then gen-
erated by fitting the final absorbance ratios using Prism 6
software (Graphpad, CA, USA). Additionally, 2  104 LT2-MYC
cells were seeded per well in Nunc 6-well plates and cultured for
24 h at 37 C with 5% CO2. Cells were then treated with PBS,
nanodiamond, 100 nMof Epirubicin and EPND respectively. Live
cell numbers were determined following Trypan blue staining
every day for 5 days.
Side Population Analysis by Flow Cytometry. For in vitro side
population analysis, 0.7  106 LT2-MYC cells were seeded in
Nunc 10 cm cell culture dishes. The following day, PBS, nano-
diamond, 100 nMand 200 nMof Epirubicin or EPNDwere added
to each plate respectively and treated for 1 h following by
washing with 1  PBS, replacing with fresh RPMI media and
incubating in 37 C for 48 h, withwashing using 1 PBS at every
24 h. Live cells were counted using trypan blue staining at 48 h.
Subsequently, cells were collected and filtered through a 40 μm
cell strainer (BD Bioscience, NJ, USA) to obtain single-cell
suspensions and aliquoted in 1 mL of RPMI media at 0.5 
106 cells/mL. Pretreatment of verapamil was done by incubating
cells in 37C water bath with 100 mM fresh-made verapamil 15
min before staining Hoechst Dye.
Hoechst Dye staining was performed by incubating cells in
37C water bath with 5 μL Hoechst dye 33342 (1 mg/mL) for
exactly 90 min. After staining, cells were washed with 7 mL
HBSSþ, collected by centrifuging at 1000 rpm, 5min. Cells were
resuspended in 500 μL HBSSþ. PI was then added at 0.2 μg/mL
right before analysis to exclude dead cells. Hoechst 33342 was
excitedwith the ultraviolet laser of LSRII (BD Bioscience, NJ, USA)
at 350 nm and fluorescence emission was measured with
405/BP30 (Hoechst blue) and 570/BP20 (Hoechst red) optical
filters. PI labeling was measured through the 630/BP30 filter for
the discrimination of dead cells. side population gating was
identified as the absence of cell population by verapamil
addition in PBS control. Calcein AM dye staining was performed
by incubating cells with 10 μM calcein AM dye for 30 min.
Calcein AM will only be taken up and metabolized by live cells
and then emit florescent signal at 520 nm. For colony formation
spheroid assay, SP, Nonside population and total live cells were
sorted using Verapamil gating by BD FacsAria II. Thirty cells
of each population were seeded into 1 well of 96-well plate
following by treatment of PBS, nanodiamond, Epirubicin
(50 nM and 100 nM), EPND (50 nM and 100 nM). Colony forming
units were counted following 7, 14, and 21 days of growth in
supplemented serum-free DMEM media (Supporting Informa-
tion Table S2).
For in vivo side population analysis, liver tumor tissues were
isolated and diced into 13 mm pieces before treating with
2 mg/mL of collagenase/Dispase (Roche, IN, USA) for 15 min at
37 C. Afterwhich, tumor cell solutionwas sieved through sterile
medical gauze (Supplier, location) and centrifuged for 5 min at
1000 rpm, 4 C. Cells were then resuspended with PBS contain-
ing 2% FBS and filtered through a 70 μm cell strainer (Fisher
Scientific, MA, USA) and then a 40 μm cell strainer. Thereafter,
cells were centrifuged and resuspended in 1  red blood cell
lysis buffer, incubated on ice for 10 min and then washed three
timeswith PBS containing 2%FBS. Aliquots of 0.5 106 cells/mL
from each tumors were resuspended in 1 mL of RPMI media.
Flow cytometry analysis for in vivo cells from MYC-driven
tumors were performed in the same manner as in vitro
experiments.
In Vivo Drug Treatment and Tumor-initiation Evaluation. MYC-in-
duced hepatic tumor-bearingmicewere treatedwith Epirubicin
or EPND at 5 mg/kg, using PBS and nanodiamond as controls
through lateral tail vein injection 6 weeks after hydrodynamic
transfection. Drug treatment was carried out 4 times at every 3 d
interval. Three days after the last dose, mice were sacrificed and
tumors were isolated for secondary tumor-initiation allograft
experiments and TUNEL staining. For allograft experiments, live
cells from excised tumors were sorted using BD FACSAria (BD
Bioscience, NJ, USA) based on PI stain exclusion. 300 cells from
Epirubicin and EPND-treated mice were injected into the hind-
quarters of 6-week-old FVB/N mice with reduced-growth factor
Matrigel (BD Bioscience, NJ, USA). Tumors were observed on a
weekly basis until approximately 1.5 cm in diameter before they
were isolated. Sizes of tumors were measured using a caliper
and calculated using the equation V = (a 3 b 3 b)/2, where a
indicated the length (mm) and b indicated the width (mm) of
the tumor, and V is the final volume (mm3). Survival study was
performed using 6-week old healthy FVB/N mice. PBS, nano-
diamond, Epirubicin (20 mg/kg) and EPND (20 mg/kg) were
injected respectively through tail vein every 3 days. Bodyweight
was measured daily and KaplanMeier survival analysis was
performed following study. All animal studies were done ac-
cording to approved protocols by the NUS Institutional Animal
Care and Use Committee, Singapore.
Apoptosis Assay. For in vitro apoptosis, 1  104 LT2-Myc cells
were seeded per well on a Nunc Lab-Tek 2-well chamber slide
and cultured for 24 h at 37 C with 5% CO2. Cells were
subsequently treated with IC25, IC50 or IC90 concentrations of
Epirubicin or EPND for 48 h. For in vivo apoptosis, treated tissues
were embedded in paraffin and cut into slides. Staining was
done using ApopTag Fluoresein In Situ Apoptosis Detection Kit
(Cat. No. S7110) (Millipore, MA, USA) for detection of apoptotic
cells in liver tissue samples from the mice that were sacrificed.
The slides were deparaffinized, pretreated with Proteinase K,
then treated with Tdt Enzyme at 37 C for 1 h and last stained
with antidigoxigenin antibody. This assay utilizes an antidigox-
igenin antibody conjugated to a Fluorescein reporter molecule,
providing an indirect TUNEL staining method.
Statistical Analysis. All experimental data were at least per-
formed in triplicates, the results averaged, and the standard
deviation (SD) or standard error of the mean (SEM) calculated.
Unpaired Student's t test was used for statistical comparison of
2 different independent groups. A probability value of p < 0.05
was accepted as statistically significant.
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